Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that its Board of Directors has unanimously appointed of Dr. Alexandre LeBeaut, MD as Chairman of the Board, effective immediately. Dr. LeBeaut has over two decades of global R&D leadership experiences, successfully bringing multiple medicines to […]
Significant appointments of experienced drug development and financial experts – Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut Versameb AG (“Versameb”), transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut to its […]
Optimum Strategic Communications is pleased to support Versameb during World Continence Week, a company raising awareness of the high unmet medical need of patients suffering with Stress Urinary Incontinence (SUI) and continence related issues which impacts the lives of millions of patients worldwide. Versameb’s Chief Executive Officer, Klaas Zuideveld to present on the Company’s proprietary […]
A year after the establishment of the mRNA Vaccine Technology Transfer Hub, Afrigen and Univercells enter a new agreement to develop the first African-own COVID-19 vaccine CAPE TOWN (SOUTH AFRICA) & BRUSSELS (BELGIUM), JUNE 21, 2022 – One year since the establishment of the mRNA Vaccine Technology Transfer Hub, a collaboration between two of the […]
Article by Dr Roger Dmochowski, Professor of Urology & Advisory Board Member of Versameb
